More recently, preclinical and clinical data have suggested that RT can also produce immune‐stimulating effects through “immunogenic cell death (ICD).” This death of cancer cells induces the release of tumor‐associated antigens but also the production of “danger signals” also named damage‐associated molecular patterns such as calreticulin, high‐mobility group box 1protein (HMGB1), and adenosine triphosphate (ATP). This evidence concerns the gene HMGB1 and cancer.